Comparative Pharmacology
Head-to-head clinical analysis: BROMANYL versus BROMFED DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMANYL versus BROMFED DM.
BROMANYL vs BROMFED-DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromanyl is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also exhibits weak antagonism at NMDA receptors, which may contribute to its analgesic effects and reduced tolerance development.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that acts on the medullary cough center to suppress cough.
10 mg orally three times daily
1 capsule (brompheniramine maleate 6 mg, dextromethorphan HBr 30 mg) orally every 6 hours, not to exceed 4 capsules per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged to 24-36 hours in severe hepatic impairment, requiring dose adjustment.
Brompheniramine: 24–36 h; pseudoephedrine: 5–8 h; dextromethorphan: 2–4 h (CYP2D6 extensive metabolizers) or up to 24 h (poor metabolizers).
Renal excretion of unchanged drug accounts for 30-40% of elimination; hepatic metabolism to inactive glucuronide conjugates accounts for 50-60%; fecal excretion is minimal (<5%).
Renal: 60–70% unchanged (brompheniramine); hepatic metabolism and renal excretion of metabolites (dextromethorphan: O-demethylation; pseudoephedrine: 70–90% unchanged in urine). Biliary/fecal: <5%.
Category C
Category C
Cough and Cold Combination
Cough and Cold Combination